AMRI has completed the following in its Bacterial Infection Program:
Following characterization of the active samples from the screens, both broad and narrow spectrum antibiotics with relatively large in vitro therapeutic indices (relative to mammalian cell-lines) and cidal activity have been identified.
Despite recent successes, antibiotic therapy remains in a precarious position due to the growing trend of antibiotic resistance. A recent release by the National Institute of Allergy and Infectious Diseases (April 2006) reported that:
Since vancomycin resistance now exists in S. aureus, it is expected to increase at rates similar to those witnessed for vancomycin-resistant enterococci, becoming endemic in U.S. hospitals by 2015. Studies in Europe show similar findings.
The incidence rate of infections caused by community-acquired, methicillin-resistant S. aureus (CA-MRSA) has also risen, increasing 17-fold in AIDS patients between 2003 and 2005 (Infectious Disease News, October 2006).